A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Trial · NCT02692716
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke | Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period. | Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time From Randomisation to First Occurrence of an Expanded Composite Cardiovascular Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, UAP Requiring Hospitalisation or Hospitalisation for Heart Failure | Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period. | Overall number of participants analyzed = FAS which comprised all randomised participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period. | Overall number of participants analyzed = FAS which comprised all randomised participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time From Randomisation to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, Non-fatal Myocardial Infarction or Nonfatal Stroke | Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period. | Overall number of participants analyzed = FAS which comprised all randomised participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time From Randomisation to First Occurrence of Fatal or Non-fatal Myocardial Infarction | Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period. | Overall number of participants analyzed = FAS which comprised all randomised participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time From Randomisation to First Occurrence of Fatal or Non-fatal Stroke | Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period. | Overall number of participants analyzed = FAS which comprised all randomised participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time From Randomisation to All-cause Death | Maximum treatment duration is dependent on event rates and is expected to be no longer than 19 months + 5 weeks of follow-up period. | Overall number of participants analyzed = FAS which comprised all randomised participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time to First AE Leading to Permanent Trial Product Discontinuation | Maximum treatment duration is dependent on event rates and is expected to be no longer than 19 months + 38 days of ascertainment window. | Overall number of participants analyzed = FAS which comprised all randomised participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Serious Adverse Events | Maximum treatment duration is dependent on event rates and is expected to be no longer than 19 months + 38 days of ascertainment window. | Overall number of participants analyzed = FAS which comprised all randomised participants. | Events | NUMBER |
| SECONDARY | Change in Eye Examination Category | Week -3, End of treatment | Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in Pulse Rate | Week 0, End of treatment | Overall number of participants analyzed = number of participants with available data. | Beats/minute | MEAN |
| SECONDARY | Change in Systolic and Diastolic Blood Pressure | Week 0, End of treatment | Overall number of participants analyzed = number of participants with available data. | mmHg | MEAN |
| SECONDARY | Change in Glycosylated Haemoglobin (HbA1c) | Week 0, End of treatment | Overall number of participants analyzed = number of participants with available data. | Percentage of HbA1c | MEAN |
| SECONDARY | Change in Body Weight | Week 0, End of treatment | Overall number of participants analyzed = number of participants with available data. | Kg | MEAN |
| SECONDARY | Change in Total Cholesterol - Ratio to Baseline | Week 0, End of treatment | Overall number of participants analyzed = number of participants with available data. | Ratio of total cholesterol | GEOMETRIC_MEAN |
| SECONDARY | Change in LDL-cholesterol - Ratio to Baseline | Week 0, End of treatment | Overall number of participants analyzed = number of participants with available data. | Ratio of LDL-cholesterol | GEOMETRIC_MEAN |
| SECONDARY | Change in HDL-cholesterol - Ratio to Baseline | Week 0, End of treatment | Overall number of participants analyzed = number of participants with available data. | Ratio of HDL-cholesterol | GEOMETRIC_MEAN |
| SECONDARY | Change in Triglycerides - Ratio to Baseline | Week 0, End of treatment | Overall number of participants analyzed = number of participants with available data. | Ratio of triglycerides | GEOMETRIC_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02692716/outcomes